Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptor, ErbB-2 | 13 | 2025 | 514 | 3.030 |
Why?
|
Breast Neoplasms | 22 | 2025 | 2498 | 2.800 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2025 | 717 | 1.330 |
Why?
|
Trastuzumab | 9 | 2025 | 134 | 1.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 1214 | 0.960 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2011 | 25 | 0.850 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2025 | 111 | 0.850 |
Why?
|
NF-kappa B | 6 | 2011 | 455 | 0.840 |
Why?
|
Curcumin | 3 | 2011 | 41 | 0.800 |
Why?
|
Gene Expression Regulation, Neoplastic | 9 | 2021 | 1893 | 0.760 |
Why?
|
Azadirachta | 2 | 2011 | 2 | 0.750 |
Why?
|
Signal Transduction | 16 | 2025 | 4501 | 0.740 |
Why?
|
Plant Extracts | 2 | 2011 | 119 | 0.670 |
Why?
|
Estrogen Receptor alpha | 4 | 2021 | 468 | 0.620 |
Why?
|
Neuroblastoma | 4 | 2011 | 520 | 0.620 |
Why?
|
Apoptosis | 6 | 2019 | 1789 | 0.610 |
Why?
|
Neoadjuvant Therapy | 6 | 2023 | 337 | 0.570 |
Why?
|
Antineoplastic Agents | 4 | 2021 | 1660 | 0.560 |
Why?
|
Gamma Rays | 3 | 2011 | 49 | 0.540 |
Why?
|
Gene Fusion | 1 | 2016 | 55 | 0.510 |
Why?
|
Biomarkers, Tumor | 7 | 2023 | 1484 | 0.510 |
Why?
|
Radiation, Ionizing | 2 | 2011 | 41 | 0.450 |
Why?
|
Cell Line, Tumor | 15 | 2025 | 3337 | 0.430 |
Why?
|
Carrier Proteins | 2 | 2020 | 1022 | 0.430 |
Why?
|
Gene Rearrangement | 1 | 2014 | 320 | 0.400 |
Why?
|
Rosaceae | 1 | 2011 | 1 | 0.380 |
Why?
|
Molecular Targeted Therapy | 4 | 2025 | 354 | 0.380 |
Why?
|
Protein Kinase Inhibitors | 3 | 2025 | 529 | 0.380 |
Why?
|
Transcription Factor RelA | 1 | 2011 | 53 | 0.370 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 74 | 0.360 |
Why?
|
Quinazolines | 3 | 2023 | 174 | 0.360 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2011 | 99 | 0.360 |
Why?
|
Superoxide Dismutase | 2 | 2010 | 137 | 0.360 |
Why?
|
Mice, Nude | 5 | 2025 | 707 | 0.350 |
Why?
|
Digestive System | 1 | 2010 | 60 | 0.350 |
Why?
|
Genes, p53 | 1 | 2010 | 212 | 0.330 |
Why?
|
Sarcoma, Ewing | 1 | 2010 | 107 | 0.320 |
Why?
|
Receptors, Estrogen | 5 | 2021 | 797 | 0.320 |
Why?
|
Gene Expression Profiling | 5 | 2021 | 1702 | 0.320 |
Why?
|
Gene Amplification | 3 | 2019 | 228 | 0.310 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 209 | 0.300 |
Why?
|
Genomics | 1 | 2016 | 1500 | 0.300 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2011 | 681 | 0.300 |
Why?
|
Tumor Microenvironment | 2 | 2025 | 555 | 0.290 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2019 | 337 | 0.260 |
Why?
|
Female | 22 | 2025 | 66482 | 0.260 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 691 | 0.240 |
Why?
|
Protein Kinases | 2 | 2016 | 332 | 0.230 |
Why?
|
Humans | 29 | 2025 | 124593 | 0.230 |
Why?
|
Neoplasm Transplantation | 3 | 2016 | 374 | 0.230 |
Why?
|
Extracellular Matrix Proteins | 1 | 2025 | 154 | 0.230 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2011 | 64 | 0.200 |
Why?
|
Cell Survival | 4 | 2021 | 806 | 0.200 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2025 | 292 | 0.200 |
Why?
|
Prognosis | 5 | 2021 | 4625 | 0.200 |
Why?
|
Mice | 10 | 2025 | 17630 | 0.200 |
Why?
|
Carcinogenesis | 1 | 2025 | 331 | 0.190 |
Why?
|
Remission Induction | 2 | 2020 | 299 | 0.190 |
Why?
|
Brain Neoplasms | 1 | 2011 | 1207 | 0.190 |
Why?
|
Linear Energy Transfer | 2 | 2011 | 7 | 0.190 |
Why?
|
Plant Leaves | 2 | 2011 | 43 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 41 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 58 | 0.180 |
Why?
|
Pyrimidinones | 1 | 2020 | 40 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2021 | 882 | 0.170 |
Why?
|
Pyridones | 1 | 2020 | 110 | 0.170 |
Why?
|
Mevalonic Acid | 1 | 2019 | 19 | 0.160 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 209 | 0.160 |
Why?
|
Pyridines | 1 | 2021 | 229 | 0.160 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 256 | 0.160 |
Why?
|
Piperazines | 1 | 2021 | 236 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 113 | 0.160 |
Why?
|
Cinnamates | 1 | 2018 | 15 | 0.160 |
Why?
|
Brain | 1 | 2010 | 2983 | 0.150 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2018 | 100 | 0.150 |
Why?
|
Animals | 10 | 2025 | 34072 | 0.150 |
Why?
|
Lymphocytes | 1 | 2019 | 406 | 0.140 |
Why?
|
Indoles | 1 | 2018 | 179 | 0.140 |
Why?
|
Oncogene Addiction | 1 | 2017 | 3 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2019 | 762 | 0.140 |
Why?
|
Precision Medicine | 1 | 2019 | 319 | 0.130 |
Why?
|
RNA-Binding Proteins | 1 | 2020 | 573 | 0.130 |
Why?
|
Transcription, Genetic | 3 | 2011 | 1697 | 0.130 |
Why?
|
RNA, Small Interfering | 2 | 2016 | 660 | 0.130 |
Why?
|
Gene Expression | 1 | 2020 | 1561 | 0.120 |
Why?
|
Genomic Instability | 1 | 2016 | 228 | 0.120 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 1062 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 486 | 0.120 |
Why?
|
Cell Proliferation | 3 | 2018 | 2285 | 0.110 |
Why?
|
Ki-67 Antigen | 1 | 2014 | 113 | 0.110 |
Why?
|
Open Reading Frames | 1 | 2014 | 211 | 0.110 |
Why?
|
Cell Separation | 1 | 2014 | 227 | 0.110 |
Why?
|
Radiation Tolerance | 2 | 2011 | 48 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 1689 | 0.110 |
Why?
|
Follow-Up Studies | 2 | 2019 | 5145 | 0.100 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 279 | 0.100 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 617 | 0.100 |
Why?
|
Treatment Outcome | 3 | 2023 | 12322 | 0.100 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 2043 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.100 |
Why?
|
Flow Cytometry | 1 | 2014 | 797 | 0.100 |
Why?
|
Aniline Compounds | 1 | 2011 | 18 | 0.100 |
Why?
|
Aminoquinolines | 1 | 2011 | 35 | 0.100 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2011 | 13 | 0.100 |
Why?
|
NF-KappaB Inhibitor alpha | 1 | 2011 | 36 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 371 | 0.100 |
Why?
|
I-kappa B Proteins | 1 | 2011 | 41 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2020 | 1248 | 0.090 |
Why?
|
Time Factors | 2 | 2011 | 6292 | 0.090 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 541 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 882 | 0.090 |
Why?
|
Cell Movement | 1 | 2014 | 836 | 0.090 |
Why?
|
Infrared Rays | 1 | 2010 | 23 | 0.090 |
Why?
|
bcl-2-Associated X Protein | 1 | 2010 | 71 | 0.090 |
Why?
|
ErbB Receptors | 1 | 2011 | 281 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 1758 | 0.080 |
Why?
|
Fruit | 1 | 2011 | 219 | 0.080 |
Why?
|
Telomerase | 1 | 2011 | 160 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 173 | 0.080 |
Why?
|
DNA Primers | 1 | 2010 | 657 | 0.080 |
Why?
|
Transfection | 1 | 2011 | 1061 | 0.080 |
Why?
|
Transcriptional Activation | 1 | 2010 | 484 | 0.080 |
Why?
|
Phenotype | 2 | 2016 | 4256 | 0.070 |
Why?
|
Tamoxifen | 2 | 2020 | 363 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1284 | 0.070 |
Why?
|
RNA, Messenger | 2 | 2011 | 2816 | 0.070 |
Why?
|
MCF-7 Cells | 2 | 2018 | 222 | 0.070 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 1586 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2010 | 1231 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 666 | 0.070 |
Why?
|
Phosphorylation | 2 | 2021 | 1615 | 0.060 |
Why?
|
Base Sequence | 1 | 2010 | 3090 | 0.060 |
Why?
|
DNA | 1 | 2011 | 1597 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 3153 | 0.060 |
Why?
|
Models, Biological | 1 | 2010 | 1459 | 0.060 |
Why?
|
Oxidative Stress | 1 | 2010 | 802 | 0.060 |
Why?
|
Laminin | 1 | 2025 | 69 | 0.060 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2020 | 505 | 0.060 |
Why?
|
Cytokines | 1 | 2009 | 1290 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2009 | 1022 | 0.050 |
Why?
|
Mutation | 2 | 2017 | 5825 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 4406 | 0.050 |
Why?
|
Up-Regulation | 2 | 2016 | 862 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 85 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2020 | 89 | 0.040 |
Why?
|
Dasatinib | 1 | 2020 | 40 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2020 | 89 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 71 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 68 | 0.040 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 355 | 0.040 |
Why?
|
Breast | 1 | 2020 | 214 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 310 | 0.040 |
Why?
|
Radiation Dosage | 2 | 2009 | 135 | 0.040 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 165 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 361 | 0.040 |
Why?
|
Heterografts | 1 | 2018 | 171 | 0.040 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
Estradiol | 1 | 2018 | 535 | 0.030 |
Why?
|
Estrogens | 1 | 2018 | 513 | 0.030 |
Why?
|
Survival Analysis | 1 | 2020 | 1496 | 0.030 |
Why?
|
Gene Silencing | 1 | 2016 | 235 | 0.030 |
Why?
|
Middle Aged | 3 | 2020 | 26714 | 0.030 |
Why?
|
Drug Design | 1 | 2016 | 147 | 0.030 |
Why?
|
Cell Cycle | 1 | 2016 | 610 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1016 | 0.030 |
Why?
|
DNA Damage | 1 | 2016 | 513 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2020 | 2876 | 0.030 |
Why?
|
I-kappa B Kinase | 1 | 2011 | 61 | 0.020 |
Why?
|
Aged | 2 | 2020 | 19703 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 240 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2011 | 301 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2021 | 4350 | 0.020 |
Why?
|
Genome, Human | 1 | 2016 | 1273 | 0.020 |
Why?
|
Algorithms | 1 | 2016 | 1619 | 0.020 |
Why?
|
Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 9 | 0.020 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2009 | 46 | 0.020 |
Why?
|
Adult | 2 | 2020 | 29438 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2019 | 6533 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2009 | 244 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 669 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 1327 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2009 | 358 | 0.020 |
Why?
|
Young Adult | 1 | 2019 | 9014 | 0.020 |
Why?
|